Study of BRIUMVI in breast milk
Part of Brain & nervous system, Immune system & allergy clinical trials.
This study looks at how much BRIUMVI (ublituximab) gets into breast milk. It helps understand if the drug is safe for breastfed babies whose mothers are already taking it for relapsing multiple sclerosis.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have already decided to take BRIUMVI for relapsing MS (including CIS, RRMS, or active SPMS).
- You are willing to breastfeed or pump regularly during the study.
- You plan to feed your baby breast milk throughout the study and are not weaning.
- Your baby was born at 35 weeks or later and is growing well (weight above the 10th percentile).
- You have not had breast implants, reductions, or mastectomy, and you have no active breast infection or other condition that would prevent breastfeeding.
- You are not taking aspirin, tetracyclines, or fluoroquinolones (which can be harmful to babies).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how well BRIUMVI (a medicine for relapsing multiple sclerosis) works for people in everyday life. Researchers want to see how people do when they first start the medication.
This Phase 3 trial tests the safety and effectiveness of a modified treatment plan using ublituximab for relapsing multiple sclerosis. It also studies how the drug behaves in the body and aims to improve disease control while monitoring side effects.
This study tests a new oral medication called remibrutinib for people with relapsing multiple sclerosis who are currently on Ocrevus. Participants will switch from Ocrevus to remibrutinib to see if it is safe and effective.
This study looks at the effects of the MS medication BRIUMVI on pregnancy and baby health. It compares women who took BRIUMVI during pregnancy to those who did not.
This study tests ublituximab (Briumvi), a treatment given as an infusion, for people recently diagnosed with relapsing MS. The goal is to see if starting this treatment early helps control MS better.
This study measures how much of the medication mirikizumab passes into breast milk when mothers take it for their approved medical condition. The goal is to understand if it's safe for breastfeeding infants when mothers are receiving this treatment.
Hear when a new Relapsing Multiple Sclerosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.